A Study of PBFT02 in Patients With Frontotemporal Dementia and Progranulin Mutations (FTD-GRN)

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 15

Inclusion Criteria

Inclusion Criteria: 1. Documented to be a pathogenic GRN mutation carrier 2. Clinical diagnosis of frontotemporal dementia 3. Have a reliable informant / caregiver (and back-up informant / caregiver) who personally speaks with or sees the subject at least weekly 4. Living in the community (i.e., not in a nursing home); assisted living may be permitted at the discretion of the investigator Exclusion Criteria: 1. Classification of the GRN mutation as not pathogenic, likely benign variant, benign variant, or pathogenic nature unclear 2. Previous treatment with any gene therapy. Any other therapies with the potential to alter PGRN levels must be washed out for at least 5 half-lives prior to entry into this study 3. Homozygous GRN mutation carrier 4. Rosen-modified Hachinski Ischemic Scale score > 7 5. Known presence of a structural brain lesion (eg, tumor, cortical infarct) that could reasonably explain symptoms in a symptomatic subject 6. Known presence of an AD-causing mutation in PSEN1, PSEN2 or APP based on genetic testing history (if performed) 7. Previous history of Korsakoff encephalopathy, severe alcohol or substance dependence (within 5 years of onset of dementia), except where onset of increased alcohol consumption occurs at the time of FTD disease onset 8. History of untreated vitamin B12 deficiency 9. Presence of untreated hypothyroidism (thyroid stimulating hormone [TSH] > ULN and free T4 < LLN) 10. eGFR = 30 ml/min (as calculated using the CKD-EPI equation) 11. Alanine aminotransferase [ALT] or aspartate aminotransferase [AST] > 2 × ULN, or total bilirubin > ULN) 12. Respiratory failure that requires supplemental oxygen 13. Inability to provide full consent or the lack of a legally authorized caregiver with adequate contact who can provide consent 14. Any contraindication to MRI or lumbar puncture (LP) (eg, local infection, history of thrombocytopenia, coagulopathy) 15. Any contraindication to the ICM administration procedure 16. Medical conditions or laboratory or vital sign abnormalities that would increase risk of complications from intra-cisterna magna injection, anesthesia, LP, and/or MRI (e.g., fever, hypoxia, tachycardia, or evidence of active infection) 17. Immunocompromised status 18. Peripheral axonal sensory neuropathy 19. Receipt of a vaccine within 14 days of dosing 20. A positive test result for human immunodeficiency virus (HIV), human T cell leukemia virus (HTLV) type 1 or type 2, or Hepatitis B or C; a Mycobacterium tuberculosis positive test within 1 year of or determined at screening 21. Malignant neoplasia (except localized skin cancer) or a documented history of hereditary cancer syndrome 22. Any concurrent disease that, in the opinion of the investigator, may cause cognitive impairment unrelated to GRN mutations, including other causes of dementia, neurosyphilis, hydrocephalus, stroke, small vessel ischemic disease, uncontrolled hypothyroidism, or vitamin deficiency 23. Current or recent history of clinically significant suicidal ideation within the past 6 months 24. For females of childbearing potential, a positive serum pregnancy test at the screening visit, a positive serum result on Day 1 prior to administration of the investigational product, or unwillingness to have additional pregnancy tests during the study. Females of childbearing potential must use a highly effective method of birth control or engage in abstinence until 90 days postdose 25. Women who are breastfeeding 26. For sexually active men, unwillingness to use a medically accepted method of double-barrier contraception (such as a condom/diaphragm used with spermicide) or engage in abstinence from the date of screening until 90 days postdose 27. Any condition (eg, history of any disease, evidence of any current disease, any finding upon physical examination, or any laboratory abnormality) that, in the opinion of the investigator, would put the subject at undue risk or would interfere with evaluation of the investigational product or interpretation of subject safety or study results 28. Any acute illness requiring hospitalization within 30 days of enrollment 29. Failure to meet the protocol-specified coagulation test criteria: - Platelet count over 100,000 per uL - INR less than 1.5 - aPTT less than 40 seconds 30. Use of anticoagulants in the 2 weeks prior to screening, or anticipated use of anticoagulants during the study. Antiplatelet therapies may be acceptable 31. Hypersensitivity or contraindications to corticosteroid use 32. Known or suspected intolerance or hypersensitivity to PBFT02 or any of its ingredients or to closely related compounds

Exclusion Criteria

Not provided

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Number of Participants with Treatment-Related AEs and SAEs;Change in Nerve Conduction Velocity from Baseline on Nerve Conduction Studies;Change in Nerve Conduction Amplitude from Baseline on Nerve Conduction Studies;Assess Humoral Response Against the Vector and Transgene in Serum;Assess Humoral Response Against the Vector and Transgene in CSF

Secondary Outcome Measures

Name	Time	Method

Related Trials

A Phase 1, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Adult Subjects with Advanced, Relapsed or Refractory Renal Cell Carcinoma (RCC) with Clear Cell Differentiatio

RecruitingPhase 2

CRISPR Therapeutics AG

Updated 4/15/2024

First in Human Multicenter Open Name Dose-increase,Consolidation method to Study Safety drug-level in Blood & drug metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients with, without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary glands tumor

Phase 1

Jubilant Therapeutics India Limited

Updated 7/22/2024

A clinical trial to look at the safety and potential efficacy of FHD-609 in people with advanced synovial sarcoma

Phase 1

Foghorn Therapeutics Inc.

Updated 3/2/2022

A clinical trial to look at the safety and potential efficacy of FHD-609 in people with advanced synovial sarcoma

Phase 1

Foghorn Therapeutics Inc.

Updated 8/28/2023

A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered FHD-286 in Subjects with Metastatic Uveal Melanoma

Completed

Foghorn Therapeutics Inc.

Updated 4/9/2024

A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

CompletedPhase 1

AbbVie G.K.

Updated 10/17/2023

To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors

CompletedNot Applicable

Abion

Updated 6/24/2024

A PHASE 1B/2 MULTI-CENTER STUDY TO FIND A WELL TOLERATED AND SAFE AND EFFECTIVE DOSE OF ACY-1215 (RICOLINOSTAT) IN COMBINATION WITH POMALIDOMIDE AND LOW-DOSE DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA AFTER PROGRESSIVE OR RETURNING DISEASE

Phase 1

Acetylon Pharmaceuticals, Inc.

Updated 2/26/2018

Open-label study of Elotuzumab in Relapsed Multiple Myeloma

AbbVie Biotherapeutics Inc. (AbbVie)

Updated 1/27/2014

A Phase 1b/II, Multicenter, Open-Label, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Combination with Lenalidomide and Dexamethasone in Subjects with Relapsed Multiple Myeloma. Elotuzumab (formerly HuLuc63)

Phase 1

Facet Biotech Corporation

Updated 11/25/2019

A Study of PBFT02 in Patients With Frontotemporal Dementia and Progranulin Mutations (FTD-GRN)

Recruitment & Eligibility

Study & Design

Related Trials

A Phase 1, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Adult Subjects with Advanced, Relapsed or Refractory Renal Cell Carcinoma (RCC) with Clear Cell Differentiatio

First in Human Multicenter Open Name Dose-increase,Consolidation method to Study Safety drug-level in Blood & drug metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients with, without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary glands tumor

A clinical trial to look at the safety and potential efficacy of FHD-609 in people with advanced synovial sarcoma

A clinical trial to look at the safety and potential efficacy of FHD-609 in people with advanced synovial sarcoma

A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered FHD-286 in Subjects with Metastatic Uveal Melanoma

A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors

A PHASE 1B/2 MULTI-CENTER STUDY TO FIND A WELL TOLERATED AND SAFE AND EFFECTIVE DOSE OF ACY-1215 (RICOLINOSTAT) IN COMBINATION WITH POMALIDOMIDE AND LOW-DOSE DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA AFTER PROGRESSIVE OR RETURNING DISEASE

Open-label study of Elotuzumab in Relapsed Multiple Myeloma

A Phase 1b/II, Multicenter, Open-Label, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Combination with Lenalidomide and Dexamethasone in Subjects with Relapsed Multiple Myeloma. Elotuzumab (formerly HuLuc63)

Clinical Trial Alerts

Clinical Trial Alerts